Ansuvimab clinical trials
Also written MAb114.
How each study uses ansuvimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 21 Dec 2020 · EBANGA · BLA 761172 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
3 studies that test it; most in 2018 (2)
| Year | Studies |
|---|---|
| 2018 | 2 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 0 · Other 3
National Institute of Allergy and Infectious Diseases (NIAID) (2) · ANRS, Emerging Infectious Diseases (1)
Often tested with
Tested in the same studies.
ZMapp (1) · Remdesivir (1) · Atoltivimab, maftivimab, and odesivimab-ebgn drug combination (1)
Studies
Open first, then newest update. How each study uses ansuvimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Prophylaxis Vaccine Antibodies EbolaStatus unknownPhase 2ANRS, Emerging Infectious DiseasesNCT04822376Written as ansuvimab
- Investigational Therapeutics for the Treatment of People With Ebola Virus DiseaseCompletedPhase 2/3National Institute of Allergy and Infectious Diseases (NIAID)NCT03719586Written as MAb114
- Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-EBOMAB092-00-AB (MAb114), Administered Intravenously to Healthy AdultsCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT03478891Written as VRC-EBOMAB092-00-AB (MAb114)
Codes
What other systems call ansuvimab · ClinicalTrials.gg INT001484
- MeSH (NLM) C000711947ansuvimabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) TG8IQ19NG2ANSUVIMABConfirmed FDA, NLM
- RxNorm 2472152One source FDA
- NCI Thesaurus C175743AnsuvimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000711947 | ansuvimab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | TG8IQ19NG2 | ANSUVIMAB | Confirmed FDA, NLM |
| RxNorm | 2472152 | — | One source FDA |
| NCI Thesaurus | C175743 | Ansuvimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.